[go: up one dir, main page]

MXPA02005173A - Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea. - Google Patents

Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea.

Info

Publication number
MXPA02005173A
MXPA02005173A MXPA02005173A MXPA02005173A MXPA02005173A MX PA02005173 A MXPA02005173 A MX PA02005173A MX PA02005173 A MXPA02005173 A MX PA02005173A MX PA02005173 A MXPA02005173 A MX PA02005173A MX PA02005173 A MXPA02005173 A MX PA02005173A
Authority
MX
Mexico
Prior art keywords
association
decrease
diseases
bone mass
remedies
Prior art date
Application number
MXPA02005173A
Other languages
English (en)
Inventor
Maruyama Takayuki
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of MXPA02005173A publication Critical patent/MXPA02005173A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describe una composicion farmaceutica para el tratamiento de enfermedades asociadas con una disminucion en la masa osea que comprende un agonista EP4 como ingrediente activo. Un agonista EP4 que incluye un compuesto que tiene un esqueleto de prostaglandina como un representante, tiene una accion promotora sobre la formacion osea, por lo cual es util para el tratamiento y/o prevencion de enfermedades asociadas con una disminucion en la masa osea.
MXPA02005173A 1999-11-24 2000-11-22 Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea. MXPA02005173A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP33349099 1999-11-24
JP2000056534 2000-03-01
JP2000119188 2000-04-20
PCT/JP2000/008235 WO2001037877A1 (en) 1999-11-24 2000-11-22 Remedies for diseases in association with decrease in bone mass

Publications (1)

Publication Number Publication Date
MXPA02005173A true MXPA02005173A (es) 2004-02-26

Family

ID=27340604

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02005173A MXPA02005173A (es) 1999-11-24 2000-11-22 Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea.

Country Status (16)

Country Link
US (1) US6891062B2 (es)
EP (1) EP1232757B1 (es)
JP (1) JP3705360B2 (es)
KR (1) KR100654653B1 (es)
CN (1) CN1262309C (es)
AT (1) ATE452640T1 (es)
AU (1) AU783939B2 (es)
CA (1) CA2391526A1 (es)
DE (1) DE60043587D1 (es)
ES (1) ES2337333T3 (es)
HU (1) HUP0203590A3 (es)
MX (1) MXPA02005173A (es)
NO (1) NO20022442L (es)
NZ (1) NZ519101A (es)
TW (1) TWI247606B (es)
WO (1) WO2001037877A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2289140T3 (es) * 2001-07-16 2008-02-01 F. Hoffmann-La Roche Ag Derivados de 2-pirrolidona como agonistas de prostanoide.
EP1417975B1 (en) * 2001-07-23 2011-03-02 Ono Pharmaceutical Co., Ltd. Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
JPWO2003041717A1 (ja) * 2001-11-12 2005-03-03 小野薬品工業株式会社 プロスタグランジン誘導体を有効成分とする局所投与用持続性フィルム状製剤
JP2006506327A (ja) * 2002-05-23 2006-02-23 セラテクノロジーズ インコーポレイティド プロスタグランジンｅ２の受容体サブタイプｅｐ４のアンタゴニスト・ポリペプチド
EP1878741A3 (en) * 2002-05-23 2008-02-20 Theratechnologies Inc. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
WO2006075690A1 (ja) * 2005-01-14 2006-07-20 Ono Pharmaceutical Co., Ltd. 安定な医薬組成物
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
US20090074844A1 (en) 2005-04-28 2009-03-19 Ono Pharmaceutical Co., Ltd. Trenadermal absorption preparation
US7901710B2 (en) 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US7998500B2 (en) 2005-08-04 2011-08-16 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
US8202546B2 (en) 2005-08-04 2012-06-19 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US8263137B2 (en) 2005-08-04 2012-09-11 Vertical Pharmaceuticals, Inc. Nutritional supplement for women
RU2425876C2 (ru) 2006-03-24 2011-08-10 Чилдрен'З Медикал Сентер Корпорейшн Способ модулирования роста гематопоэтических стволовых клеток
EP2679221B1 (en) 2006-10-20 2020-09-23 Children's Medical Center Corporation Method to enhance tissue regeneration
WO2008050848A1 (en) 2006-10-26 2008-05-02 Ono Pharmaceutical Co., Ltd. Adhesive preparation
WO2008136519A1 (ja) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Ｅｐ４アゴニストを含有してなる細胞傷害性ｔ細胞の活性化剤
WO2009155041A2 (en) * 2008-05-28 2009-12-23 Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
EP2454227B1 (en) 2009-07-13 2020-08-19 Patheon API Services Inc. Synthesis of prostanoids
PT2785834T (pt) 2011-12-02 2020-11-13 Fate Therapeutics Inc Composição de células estaminais melhorada
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
CN107802623B (zh) 2012-07-19 2020-10-30 开曼化学股份有限公司 用于ep4介导的骨相关疾病和病症的二氟内酰胺组合物
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
EP2989098B1 (en) 2013-03-15 2017-05-10 Cayman Chemical Company, Incorporated Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
WO2014144610A1 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
CN105392505A (zh) 2013-07-19 2016-03-09 开曼化学股份有限公司 用于促进骨生长的方法、系统和组合物
KR102311896B1 (ko) 2013-09-30 2021-10-14 패턴 에이피아이 서비시즈 인코포레이티드 복분해를 사용하는 프로스타글란딘 및 프로스타글란딘 중간체의 합성 경로
EA037327B1 (ru) 2015-09-22 2021-03-12 Грейбуг Вижн, Инк. Соединения и композиции для лечения глазных расстройств

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE390917T1 (de) * 1996-12-20 2008-04-15 Pfizer Prävention und behandlung von skeletterkrankungen mit ep2 subtyp selektiven prostaglandin e2 agonisten
JPH10265454A (ja) * 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
GB2330307A (en) * 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors
US6043275A (en) * 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
WO2000015608A1 (fr) * 1998-09-14 2000-03-23 Ono Pharmaceutical Co., Ltd. Derives e de phenyl-prostaglandine a substitution-φ et medicaments les contenant comme ingredient actif
CA2346031A1 (en) * 1998-10-15 2000-04-20 Merck & Co., Inc. Methods for stimulating bone formation

Also Published As

Publication number Publication date
HUP0203590A2 (hu) 2003-03-28
AU1548501A (en) 2001-06-04
WO2001037877A1 (en) 2001-05-31
EP1232757B1 (en) 2009-12-23
NZ519101A (en) 2004-04-30
ATE452640T1 (de) 2010-01-15
ES2337333T3 (es) 2010-04-23
JP3705360B2 (ja) 2005-10-12
CN1424918A (zh) 2003-06-18
KR20020059774A (ko) 2002-07-13
KR100654653B1 (ko) 2006-12-07
NO20022442L (no) 2002-07-24
US20040209848A1 (en) 2004-10-21
CN1262309C (zh) 2006-07-05
EP1232757A4 (en) 2004-06-16
NO20022442D0 (no) 2002-05-23
AU783939B2 (en) 2006-01-05
DE60043587D1 (de) 2010-02-04
TWI247606B (en) 2006-01-21
CA2391526A1 (en) 2001-05-31
EP1232757A1 (en) 2002-08-21
US6891062B2 (en) 2005-05-10
HUP0203590A3 (en) 2006-07-28

Similar Documents

Publication Publication Date Title
MXPA02005173A (es) Composicion farmaceutica para el tratamiento de enfermedades asociadas con disminucion de masa osea.
AU3990797A (en) Sustained release formulation
AU2002318759A1 (en) Remedies for diseases with bone mass loss having EP4 agonists as the active ingredient
MY133996A (en) Compounds for the treatment of ischemia
ATE255589T1 (de) Kristallin form i von clarithromycin
MXPA04000757A (es) Remedios para enfermedades con perdida de masa de hueso que tienen agonistas ep4 como ingrediente activo.
AP9901478A0 (en) Compounds for the treatment of ischemia.
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
FI963232A0 (fi) Antimikrobisena aineena käytettävä hapotettu nitriitti
MXPA03008623A (es) Combinacion farmaceutica para el tratamiento del cancer.
BR0100558A (pt) Composições e métodos para tratar a osteoporose
NZ516513A (en) Nitric oxide donors for inducing neurogenesis
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
SE9802208D0 (sv) Novel compounds
AU2002214389A1 (en) Pharmaceutical composition containing honey for the treatment of wounds
EP0861663A3 (en) Osteoclastgenic inhibitory agent comprising interleukin-18
PH30665A (en) Aminosulfonyl urea acat inhibitors
WO2001041747A3 (de) Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs
BR0013416A (pt) Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado
SE9802209D0 (sv) Novel compounds
BR0015781A (pt) Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
WO2002024181A3 (en) The use of melatonin for induction of general anesthesia
GB9505082D0 (en) Medicament
WO2003024486A1 (en) Remedies for bone loss
PL355113A1 (en) Novel fusidic acid derivatives

Legal Events

Date Code Title Description
FG Grant or registration